معرفی
Professor Helena Danielson is a distinguished academic at Uppsala University, serving as Professor of Biochemistry since 2002. She leads the Danielson group within the Department of Chemistry - BMC (Biomedical Centre) and holds the position of Platform Scientific Director at the SciLifeLab infrastructure unit for Biophysical Screening and Characterization. Dr. Danielson is also a co-founder of Beactica Therapeutics AB, demonstrating her strong connection between academic research and commercial drug discovery applications.
Her research expertise centers on enzymology and drug discovery, with particular focus on biomolecular interaction analysis for detailed studies of enzyme-inhibitor interactions and other critical recognition processes in life sciences. Her work has extensively investigated various enzymes, primarily proteases and polymerases from viruses and other infectious organisms, or those involved in important disease processes. Dr. Danielson has over 30 years of experience in the commercial drug discovery process through collaborative research with pharmaceutical and biotechnological industry partners.
Analysis of her recent publications reveals a strong emphasis on RNA-protein interactions, epigenetic targets (particularly SMYD3), and advanced biosensor technologies for drug discovery. Her work increasingly integrates computational methods with experimental biosensor approaches, especially using Surface Plasmon Resonance (SPR) technology for fragment-based screening against challenging drug targets. The research shows progression from traditional enzyme kinetics to more sophisticated analyses of multivalent interactions, allosteric regulation, and water network effects in protein-ligand binding.
As Platform Scientific Director at SciLifeLab, Dr. Danielson oversees critical infrastructure for biophysical screening and characterization. Her group has developed numerous innovative methodologies for studying protein-ligand interactions, including multiplexed experimental strategies and sensitive detection methods. Her leadership extends to fostering collaborations between academic researchers and industry partners, facilitating the translation of basic research into practical drug discovery applications.
